risk/rewardThe risk/reward ratio for ONC has now reached a level where I am again comfortable recommending this stock to my family and friends (if they ask for my opinion).
With 3 P1’s concluded, 3 more running and looking very promising, and two more on the horizon (UAB and NCI), I have more confidence than ever that we will be seeing a major change in the trading patterns for ONC over the next several months.
Viral therapy has become more than a dream and large pharmaceutical companies will be looking to stake a claim in this area.
I believe a time will come this summer, with the start-up of P2 trials, when ONCY will consistently trade over 100,000 shares and a market cap of 500 million will be surpassed.